GlassScriptPhysician profile
Shotaro Sano
NPI 1962806851
$7,663.51
in general payments reported to CMS, 2019-2025
24 companies · $6,117 in 2025
The $6,117 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.52 · 2020: $74.41 · 2021: $88.80 · 2022: $31.50 · 2023: $351 · 2024: $945 · 2025: $6,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $1,729 · Food and Beverage: $1,000 · Long Term Medical Supply Or Device Loan: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $1,729.29 |
| Food and Beverage | $999.69 |
| Long Term Medical Supply Or Device Loan | $184.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,371.96 | 2024-2025 | |
| Integra Lifesciences Corporation | $624.50 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic, INC. | $162.50 | 2025 | Progrip |
| Braintree Laboratories, INC. | $56.38 | 2020-2023 | Suflave |
| Tela Bio, INC. | $41.43 | 2019-2020 | |
| Kerecis Limited | $38.84 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $36.72 | 2025 | Libtayo |
| Tei Biosciences INC | $30.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.60 | 2020-2021 | |
| Stryker Corporation | $24.23 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.62 | 2025 | Ultomiris |
| Angiodynamics, INC. | $22.08 | 2020 | |
| Syndax Pharmaceuticals, INC. | $21.03 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $20.89 | 2025 | |
| Geron Corporation | $20.10 | 2025 | Rytelo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $18.07 | 2021 | |
| Genmab U.S., INC. | $17.89 | 2023 | Tivdak |
| Genentech USA, INC. | $16.83 | 2025 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2025 | |
| Seagen INC. | $15.94 | 2022 | |
| Merck Sharp & Dohme LLC | $15.83 | 2024 | Keytruda |
| Amgen INC. | $13.44 | 2023 | Nplate, Vectibix, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $12.88 | 2023 | |
| Smith+Nephew, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shotaro Sano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.